HYBRID EVENT: You can participate in person at Tokyo, Japan from your home or work.
Anticancer drug development represents a dynamic and vital frontier in the ongoing pursuit of effective cancer treatments. This multifaceted process involves the identification, design, and synthesis of compounds with the potential to combat cancer cells selectively and with minimal impact on healthy tissues. The journey from conceptualization to clinical application is intricate, encompassing rigorous preclinical testing, pharmacological studies, and extensive clinical trials.
In recent years, the landscape of anticancer drug development has witnessed notable strides, with a paradigm shift towards targeted therapies and immunotherapies. Targeted therapies, exemplified by drugs like trastuzumab and imatinib, aim to interfere with specific molecules involved in cancer growth and progression. Immunotherapies, such as checkpoint inhibitors and CAR-T cell therapy, harness the power of the immune system to recognize and eliminate cancer cells. These advancements underscore a more personalized and precise approach, marking a departure from conventional chemotherapy. The ongoing quest for novel compounds, coupled with innovative research methodologies, holds promise for the continual expansion of the anticancer drug development frontier, fostering hope for improved cancer treatment outcomes in the future.
